Skip to content

Study · Not a test of the peptide alone · 2005

6 results

[Anti-HBV effect of fusion protein (TA1-IFN) in vitro].

Lu NF, Huang AL, Zheng RQ, Zhu YB, Xia ZF, Tang N, Yan G, Gao XL, Wu Y

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology1 Apr 2005Cited by 1 (Europe PMC)

PMID15850509 (opens in a new tab)PepBankPUB-15850509
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    In 2.2.15 cells, the thymosin alpha1-interferon alpha fusion protein inhibited HBsAg, with a rate that was dose-dependent and highest at 8000 U/ml.

    In plain wordsIn lab cells, a fusion protein of thymosin alpha‑1 and interferon alpha lowered hepatitis B surface antigen, most at the highest dose.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseHBsAg inhibitory rate, fusion protein
    Study

    n: not reported in source

    2.2.15 cells
    Comparator
    Fusion protein versus combination at 8000 U/ml
    Outcome group
    Antiviral activity · Infection

    Measurements

    HBsAg inhibitory rate
    72.2%
    TA1-IFN fusion protein, 8000 U/ml

    Source sentences

    Summary
    In the meantime, the inhibitory rates of fusion protein on HBsAg and HBeAg were 72.2% +/- 0.8% and 60.4% +/- 1.1% respectively, and the cell survival rate was 85.2% +/- 2.0%; In the corresponding concentration, the inhibitory rates of combination thymosin alpha 1 and interferon alpha on HBsAg and HB…
    2 context sentences
    Summary · context
    The inhibitory rate of fusion protein on HBsAg, HBeAg was dose-dependent and reached the maximum at 8000 U/ml concentration.
    Summary · context
    After 2.2.15 cells were seeded for 24 hours, drugs of five serial concentrations (8000, 4000, 2000, 1000, 500 U/ml) were added to the wells, then the medium was changed every three days.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    In 2.2.15 cells, the thymosin alpha1-interferon alpha fusion protein inhibited HBeAg, with a rate that was dose-dependent and highest at 8000 U/ml.

    In plain wordsIn lab cells, a fusion protein of thymosin alpha‑1 and interferon alpha lowered hepatitis B e antigen, most at the highest dose.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseHBeAg inhibitory rate, fusion protein
    Study

    n: not reported in source

    2.2.15 cells
    Comparator
    Fusion protein versus combination at 8000 U/ml
    Outcome group
    Antiviral activity · Infection

    Measurements

    HBeAg inhibitory rate
    60.4%
    TA1-IFN fusion protein, 8000 U/ml

    Source sentences

    Summary
    In the meantime, the inhibitory rates of fusion protein on HBsAg and HBeAg were 72.2% +/- 0.8% and 60.4% +/- 1.1% respectively, and the cell survival rate was 85.2% +/- 2.0%; In the corresponding concentration, the inhibitory rates of combination thymosin alpha 1 and interferon alpha on HBsAg and HB…
    2 context sentences
    Summary · context
    The inhibitory rate of fusion protein on HBsAg, HBeAg was dose-dependent and reached the maximum at 8000 U/ml concentration.
    Summary · context
    After 2.2.15 cells were seeded for 24 hours, drugs of five serial concentrations (8000, 4000, 2000, 1000, 500 U/ml) were added to the wells, then the medium was changed every three days.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    In 2.2.15 cells, the combination of thymosin alpha1 and interferon alpha inhibited HBsAg less than the fusion protein at the same concentration.

    In plain wordsIn lab cells, thymosin alpha‑1 mixed with interferon alpha lowered hepatitis B surface antigen less than the fusion protein did.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseHBsAg inhibitory rate, thymosin alpha1 plus interferon alpha
    Study

    n: not reported in source

    2.2.15 cells
    Comparator
    Fusion protein versus combination at 8000 U/ml
    Outcome group
    Antiviral activity · Infection

    Measurements

    HBsAg inhibitory rate
    40%
    thymosin alpha 1 plus interferon alpha

    Source sentences

    Summary
    In the meantime, the inhibitory rates of fusion protein on HBsAg and HBeAg were 72.2% +/- 0.8% and 60.4% +/- 1.1% respectively, and the cell survival rate was 85.2% +/- 2.0%; In the corresponding concentration, the inhibitory rates of combination thymosin alpha 1 and interferon alpha on HBsAg and HB…
    1 context sentence
    Summary · context
    After 2.2.15 cells were seeded for 24 hours, drugs of five serial concentrations (8000, 4000, 2000, 1000, 500 U/ml) were added to the wells, then the medium was changed every three days.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    In 2.2.15 cells, the combination of thymosin alpha1 and interferon alpha inhibited HBeAg less than the fusion protein at the same concentration.

    In plain wordsIn lab cells, thymosin alpha‑1 mixed with interferon alpha lowered hepatitis B e antigen less than the fusion protein did.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseHBeAg inhibitory rate, thymosin alpha1 plus interferon alpha
    Study

    n: not reported in source

    2.2.15 cells
    Comparator
    Fusion protein versus combination at 8000 U/ml
    Outcome group
    Antiviral activity · Infection

    Measurements

    HBeAg inhibitory rate
    34.5%
    thymosin alpha 1 plus interferon alpha

    Source sentences

    Summary
    In the meantime, the inhibitory rates of fusion protein on HBsAg and HBeAg were 72.2% +/- 0.8% and 60.4% +/- 1.1% respectively, and the cell survival rate was 85.2% +/- 2.0%; In the corresponding concentration, the inhibitory rates of combination thymosin alpha 1 and interferon alpha on HBsAg and HB…
    1 context sentence
    Summary · context
    After 2.2.15 cells were seeded for 24 hours, drugs of five serial concentrations (8000, 4000, 2000, 1000, 500 U/ml) were added to the wells, then the medium was changed every three days.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Safety outcome

    In 2.2.15 cells, the fusion protein showed a cell survival rate that was higher than with the thymosin alpha1 plus interferon alpha combination, so its cytotoxicity was weaker.

    In plain wordsIn lab cells, more cells survived the fusion protein than the thymosin alpha‑1 plus interferon alpha mixture.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableCell survival rate, fusion protein
    Study

    n: not reported in source

    2.2.15 cells
    Comparator
    Fusion protein versus combination at 8000 U/ml
    Outcome group
    Adverse events · Infection

    Measurements

    Cell survival rate
    85.2%
    TA1-IFN fusion protein

    Source sentences

    Summary
    In the meantime, the inhibitory rates of fusion protein on HBsAg and HBeAg were 72.2% +/- 0.8% and 60.4% +/- 1.1% respectively, and the cell survival rate was 85.2% +/- 2.0%; In the corresponding concentration, the inhibitory rates of combination thymosin alpha 1 and interferon alpha on HBsAg and HB…
    2 context sentences
    Summary · context
    Cytotoxicity of fusion protein was weaker than a combination of thymosin alpha 1 and interferon alpha.
    Summary · context
    After 2.2.15 cells were seeded for 24 hours, drugs of five serial concentrations (8000, 4000, 2000, 1000, 500 U/ml) were added to the wells, then the medium was changed every three days.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Safety outcome

    In 2.2.15 cells, the thymosin alpha1 plus interferon alpha combination showed a lower cell survival rate than the fusion protein.

    In plain wordsIn lab cells, fewer cells survived the thymosin alpha‑1 plus interferon alpha mixture than the fusion protein.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableCell survival rate, thymosin alpha1 plus interferon alpha
    Study

    n: not reported in source

    2.2.15 cells
    Comparator
    Fusion protein versus combination at 8000 U/ml
    Outcome group
    Adverse events · Infection

    Measurements

    Cell survival rate
    70%
    thymosin alpha 1 plus interferon alpha

    Source sentences

    Summary
    The results showed significant statistical differences between them; cell survival rate 70.0% +/- 1.9%, and the difference of the results was also significant.
    2 context sentences
    Summary · context
    Cytotoxicity of fusion protein was weaker than a combination of thymosin alpha 1 and interferon alpha.
    Summary · context
    After 2.2.15 cells were seeded for 24 hours, drugs of five serial concentrations (8000, 4000, 2000, 1000, 500 U/ml) were added to the wells, then the medium was changed every three days.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.